Published October 5, 2012 | Version v1
Journal article

Deletion of the TNFAIP3/A20 gene detected by FICTION analysis in classical Hodgkin lymphoma

  • 1. Section of Microbiology and Immunology, Tokyo Medical and Dental University Graduate School of Health Care Sciences, Tokyo (Japan)
  • 2. Hematology Division, National Cancer Center Hospital, Tokyo (Japan)
  • 3. Early Carcinogenetic Division, Research Institute, National Cancer Center Hospital, Tokyo (Japan)
  • 4. Pathology Project for Molecular Targets, The Cancer Institute, Japanese Foundation for Cancer Research, Tokyo (Japan)
  • 5. Cancer Genomics, Faculty of Medicine, The University of Tokyo, Tokyo (Japan)
  • 6. Pathology Division, National Cancer Center Hospital, Tokyo (Japan)
  • 7. Cancer Genomics Division, National Cancer Center Research Institute, Tokyo (Japan)

Description

The TNFAIP3 gene, which encodes a ubiquitin-modifying enzyme (A20) involved in the negative regulation of NF-κB signaling, is frequently inactivated by gene deletions/mutations in a variety of B-cell malignancies. However, the detection of this in primary Hodgkin lymphoma (HL) specimens is hampered by the scarcity of Hodgkin Reed-Sternberg (HR-S) cells even after enrichment by micro-dissection. We used anti-CD30 immunofluorescence with fluorescence in-situ hybridization (FISH) to evaluate the relative number of TNFAIP3/CEP6 double-positive signals in CD30-positive cells. From a total of 47 primary classical Hodgkin lymphoma (cHL) specimens, 44 were evaluable. We found that the relative numbers of TNFAIP3/CD30 cells were distributed among three groups, corresponding to those having homozygous (11%), heterozygous (32%), and no (57%) deletions in TNFAIP3. This shows that TNFAIP3 deletions could be sensitively detected using our chosen methods. Comparing the results with mutation analysis, TNFAIP3 inactivation was shown to have escaped detection in many samples with homozygous deletions. This suggests that TNFAIP3 inactivation in primary cHL specimens might be more frequent than previously reported

Availability note (English)

Available from http://dx.doi.org/10.1186/1471-2407-12-457; Available from http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3519598

Additional details

Publishing Information

Journal Title
BMC cancer (Online)
Journal Volume
12
Journal Page Range
p. 457
ISSN
1471-2407

INIS

Country of Publication
United Kingdom
Country of Input or Organization
International Atomic Energy Agency (IAEA)
INIS RN
46111813
Subject category
S60: APPLIED LIFE SCIENCES;
Descriptors DEI
ENZYMES; FLUORESCENCE; GENES; INACTIVATION; IN-SITU HYBRIDIZATION; LYMPHOMAS; MUTATIONS; REGULATIONS; SIGNALS
Descriptors DEC
BIOTECHNOLOGY; DISEASES; EMISSION; GENETIC ENGINEERING; IMMUNE SYSTEM DISEASES; LAWS; LUMINESCENCE; NEOPLASMS; NUCLEIC ACID HYBRIDIZATION; ORGANIC COMPOUNDS; PHOTON EMISSION; PROTEINS

Optional Information

Copyright
Copyright (c)2012 Nomoto et al.
Notes
PMCID: PMC3519598; PUBLISHER-ID: 1471-2407-12-457; PMID: 23039325; OAI: oai:pubmedcentral.nih.gov:3519598; licensee BioMed Central Ltd.